TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the retirement of Chief Financial Officer Tom Fitzgerald, who has served in the role since July 2018 and will resign as CFO and a director effective immediately while continuing to provide transition services. The company named John Tattory interim CFO, effective immediately. Tattory has more than 25 years of financial and operational management and leadership experience across pharmaceutical, medical device and biotechnology companies, including roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics and Windtree Therapeutics. He currently serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.
The leadership change comes at a critical time for TransCode Therapeutics. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. As a clinical stage company, TransCode relies heavily on investor confidence and efficient capital management to fund its research and development efforts. The appointment of an interim CFO with extensive life science financial experience could help ensure continuity and maintain financial discipline during this pivotal period.
Investors and industry observers will be watching closely to see how Tattory’s background aligns with TransCode’s strategic goals. His experience at large pharmaceutical firms like Bristol-Myers Squibb and his consulting work with private life science companies may bring fresh perspectives on financial operations, fundraising, and cost management. However, the interim nature of his appointment also introduces some uncertainty, as the company may eventually seek a permanent CFO. The transition period, during which Fitzgerald will provide transition services, is intended to smooth the handover and minimize disruption.
The announcement was made via a press release, which can be viewed in full at https://nnw.fm/8G3ik. For ongoing updates on TransCode Therapeutics, investors can visit the company’s newsroom at https://nnw.fm/RNAZ. Additionally, NetworkNewsWire offers a range of communication solutions, and more information is available at https://www.NetworkNewsWire.com. The full terms of use and disclaimers applicable to NetworkNewsWire content can be found at https://www.NetworkNewsWire.com/Disclaimer.
The change in financial leadership could have implications for TransCode’s ability to secure funding, manage expenses, and communicate its financial position to shareholders. With Tattory’s deep experience in life sciences, the company may benefit from a steady hand as it navigates the complex financial landscape of clinical-stage biotechnology. The retirement of a long-serving CFO like Fitzgerald, who has been with the company since 2018, also signals a potential shift in corporate governance. Stakeholders will be eager to see whether the interim appointment leads to a permanent hire and how the company’s financial strategy evolves under new leadership. As TransCode continues to advance its promising pipeline, the CFO transition will be a key factor in maintaining momentum and investor trust.
